A Multicenter, Open-label, Single-arm, Expanded Access Protocol of AMG 510 (pINN Sotorasib) for the Treatment of Subjects with Previously Treated Locally Advanced Unresectable/Metastatic NSCLC with KRAS p.G12C Mutation

drug protocol number
20190436
drug sponsor
Amgen
drug study
AMG 510 (Sotorasib)
drug trial site
King Fahad Specialist Hospital (Dammam)
drug status
Ongoing
drug phase